ORTEXORTEX News
Tracking SON? Get live short interest, options flow, and signals on ORTEX.Sign up free →
SO
Earnings PreviewSON

SON Shorts Rise, Options Tell a Different Story

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 20 Oct 2026, 04:01

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Sonoco Products Company heads into its Q3 print on October 21 with a notable split between what short sellers and options traders are signalling.

Short interest has risen meaningfully into the print, making it the dominant positioning story. At 11.3% of free float, SI has climbed roughly 9% over the past month and 5% over the past week alone, reaching its highest level in the recent window. The ORTEX short score has followed, ticking up from 68.8 to 70.7 over the past two weeks, ranking in the second percentile of the universe on short score. Yet the lending market offers no sign of a squeeze setup: availability is ample at 228%, well above the 52-week low of 173%, and cost to borrow remains near the floor at 0.55%. Days to cover stands at roughly 10 days, a long runway but not an unusual one for a mid-cap industrial.

Options traders are pointing in the opposite direction. Call volume has surged relative to puts, pushing the put/call ratio down to 0.145, nearly four standard deviations below its 20-day mean of 0.30. That is close to the 52-week low of 0.04 and is one of the most aggressive call-skewed readings this stock has seen in a year. The divergence between rising short interest and extreme call-side positioning is the sharpest tension heading into the report.

The analyst community has spent October cutting targets ahead of the print. Wells Fargo trimmed its target to $53 from $56 on October 19, maintaining Equal-Weight. Truist Securities, which retains a Buy rating, lowered its target to $62 from $68 a week earlier. UBS cut to $51 from $61. The mean target stands at $59, implying roughly 18% upside from the $49.80 close, though the direction of travel is clearly downward. Bank of America downgraded to Neutral in early September, cutting its target from $69 to $60, marking a broader shift in Street conviction. The bull case rests on Sonoco's position as the largest North American uncoated recycled board producer, the potential for multiple re-rating as the portfolio shifts toward less-cyclical consumer markets, and discipline around capital allocation. Bears see customer inventory headwinds and cyclical exposure in segments still vulnerable to macro softness.

The CEO made a notable open-market purchase of $249,000 on August 7 without a 10b5-1 plan in place, a discretionary buy at prices well above the current level. That is worth noting as a signal of management conviction at the time, though the stock has since retreated. On the ownership side, Dimensional Fund Advisors crossed the 5% threshold and filed a fresh Schedule 13G on October 8. No activist 13D filers are on the register.

Packaging peers have broadly rallied on the week: AMCR up 5.1%, IP up 6.0%, and SLGN up 6.7%. Sonoco's 3.7% weekly gain keeps pace but has not led the group. The stock last reported in late July and rose roughly 3% on the day and 5% over the following five trading sessions, a reaction that favoured the bulls.

The October 21 print will test whether the portfolio shift toward consumer-oriented markets is delivering the volume and margin stability that justifies a higher multiple, or whether the recent target cuts from the Street reflect a more durable reset in earnings expectations.

Stocks in this article

See the live data behind this article on ORTEX.

Open SON on ORTEX →

How this article was generated

Generated
20 Oct 2026, 04:18
Data as of
20 Oct 2026, 04:01
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.